Evaluating effects of switching anti-vascular endothelial growth factor drugs for age-related macular degeneration and diabetic macular edema

JAMA Ophthalmology

Volumn 135, Issue 2, 2017, Pages 145-149

  Ferris, Frederick L ^a   Maguire, Maureen G ^b   Glassman, Adam R ^c   Ying, Gui Shuang ^b   Martin, Daniel F ^d  

^a NATIONAL EYE INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c JAEB CENTER FOR HEALTH RESEARCH   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CENTRAL RETINAL THICKNESS; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT RESPONSE; VISUAL ACUITY;

EID: 85014530678     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2016.4820     Document Type: Article

References (6)

1. Ciulla TA, Hussain RM, Ciulla LM, Sink B, Harris A. Ranibizumab for diabetic macular edema refractory to multiple prior treatments. Retina. 2016;36(7): 1292-1297.
2. Heussen FM, Shao Q, Ouyang Y, Joussen AM, Müller B. Clinical outcomes after switching treatment from intravitreal ranibizumab to aflibercept in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2014;252(6):909-915.
3. Lim LS, NgWY, Mathur R, et al. Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab. Clin Ophthalmol. 2015;9:1715-1718.
4. Moisseiev E, Katz G, Moisseiev J, et al. Switching treatment for neovascular age-related macular degeneration from bevacizumab to ranibizumab: who is likely to benefit from the switch? Retina. 2015;35(7):1323-1330.
5. Elman MJ, Aiello LP, Beck RW, et al; Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064-1077. e35.
6. Ying GS, Maguire MG, Daniel E, et al; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. Association of baseline characteristics and early vision response with 2-year outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology. 2015;122(12):2523-31. e1.